On December 14, 2023, the Board of Directors of Ionis Pharmaceuticals, Inc. appointed Michael Yang as a member of the Company?s Board effective immediately. Mr. Yang?s appointment expands the total number of Ionis Board members to 10. Mr. Yang has more than 20 years of broad senior level leadership experience in biotech, pharmaceutical and medical device companies, where he launched new platforms, expanded global revenues and diversified product lines.

He most recently served as President, Chief Executive Officer and Board member of ViaCyte, which was acquired by Vertex in 2022. Prior to ViaCyte, Mr. Yang was Executive Vice President and Chief Commercial Officer at Acadia Pharmaceuticals from 2017 to 2021. During his tenure, Acadia transformed the standard of care for patients with Parkinson's disease psychosis.

Prior to Acadia, Mr. Yang was President of Janssen Biotech Inc., where he was responsible for building Janssen's U.S. immunology business, generating more than $8 billion in annual revenues.